Tissue Transglutaminase Antibody

If you're investigating celiac disease, a stool tissue transglutaminase antibody result cannot reliably confirm or exclude it. Research shows that these antibodies can be detected in stool, but studies have produced inconsistent results. This remains an exploratory marker, and its usefulness for diagnosing celiac disease, measuring gut inflammation or monitoring recovery hasn't been established.

What the Antibody Is

Tissue transglutaminase is an enzyme found throughout the body, including the intestine. It helps link proteins together and contributes to tissue repair. In celiac disease, it also modifies fragments of gluten from wheat, barley and rye. In genetically susceptible people, the immune response to these fragments includes production of antibodies against the enzyme itself.

Immune cells in the intestinal lining can produce these antibodies, and researchers have detected them in intestinal tissue, blood and stool. These are different measurements. Finding antibodies in a biopsy sample doesn't establish how much will be recovered from stool, and a stool reading hasn't been shown to measure the amount of damage to the small intestine.

Almost everyone with celiac disease carries an associated HLA-DQ2 or HLA-DQ8 gene combination. Most people who carry these combinations never develop the disease. In someone who does develop celiac disease, the immune response to gluten can damage the small projections along the intestinal lining that absorb nutrients.

What This Stool Result Measures

This test looks for antibodies against tissue transglutaminase in a stool sample using an immunoassay. An immunoassay detects binding between a target and laboratory reagents. The result is reported as an index on the laboratory's scale.

The test information doesn't specify which antibody class it detects. Published stool studies have measured IgA or secretory IgA antibodies using particular collection and processing methods. Their results cannot be assumed to describe the performance of this assay. There is no established, broadly validated stool index that diagnoses celiac disease or identifies an optimal level.

Celiac Disease

A pediatric validation study found that a commercial stool secretory IgA assay missed most biopsy-confirmed celiac disease. The anti-tTG analysis included 20 children with celiac disease and a control group with other gastrointestinal conditions. It detected only 10% of the celiac cases, while nearly all controls tested negative. The small sample makes those estimates uncertain, and the study did not validate this catalog test.

Other small studies found higher stool anti-tTG IgA in untreated celiac disease than in controls. They used research assays on liquid extracts prepared from stool. A later review found conflicting results across studies, so the pediatric finding shouldn't be presented as the accuracy of every stool assay. The evidence also doesn't establish that stool testing detects celiac disease earlier than blood testing.

Blood tTG-IgA has a much stronger diagnostic evidence base. In a meta-analysis of selected studies conducted in specialist settings, it detected about 91% of adult cases and 98% of childhood cases. Performance depended on the assay and population. These are blood-test findings and cannot be transferred to a stool index.

Celiac diagnosis combines blood results with your symptoms, gluten intake and, often, small-intestinal biopsies. Some children and selected adults qualify for diagnosis without a biopsy under specific specialist protocols. A blood result alone doesn't settle every case, and negative blood antibodies can occur despite celiac disease.

Crohn's Disease and Ulcerative Colitis

A small study of people with Crohn's disease or ulcerative colitis detected anti-tTG IgA in blood and in liquid extracts from stool. It reported associations with disease activity. This supports the possibility of finding these antibodies outside celiac disease, but it doesn't establish this stool index as a reliable way to diagnose or monitor inflammatory bowel disease.

Separate research examined human intestinal biopsies and antibodies released from those biopsies during laboratory culture. A minority of participants with other diagnoses, negative blood anti-tTG and normal duodenal structure showed intestinal antibody production. Some also had signs of local immune activation. This was a tissue-based finding, not a stool-test result, and it doesn't prove that tissue repair itself caused the antibody response.

A positive stool result therefore doesn't establish either celiac disease or another source of inflammation. Its ability to distinguish Crohn's disease, ulcerative colitis, infection and other causes of digestive symptoms remains unproven.

Long-Term Health Outcomes

The long-term studies discussed here measured antibodies in blood. They haven't established a way to use this stool index to predict heart disease, cancer or lifespan.

In several thousand Finnish adults followed for more than two decades, blood anti-tTG positivity had no clear association with coronary heart disease after adjustment for existing disease and other risk factors. Analyses from overlapping Finnish cohorts found no statistically clear increase in deaths from all causes or in total cancer incidence over long-term follow-up. Those findings don't exclude smaller risks or differences in particular diseases.

A German cohort of 4,633 adults found higher death rates among people with positive blood anti-tTG, with a larger relative increase reported in women than in men. The estimates were adjusted only for age and were based on few deaths among antibody-positive participants, so their precision was limited. The study couldn't determine whether unrecognized celiac disease, other illnesses or additional differences between participants explained the association. These conflicting blood findings provide no basis for estimating your long-term risk from a stool result.

When Results Can Be Misleading

• False reassurance: published stool assays have missed biopsy-confirmed celiac disease. Correct collection cannot overcome an assay's limited diagnostic sensitivity.
• Assay differences: stool preparation, the antibody class detected and the laboratory reagents differ across studies. An index from one assay isn't interchangeable with another laboratory's result or with blood antibody measurements.
• Uncertain specificity: detecting antibody binding doesn't establish the cause. Research has found anti-tTG antibodies outside celiac disease, and this assay hasn't been validated as a general measure of intestinal inflammation.
• IgA deficiency: IgA-based blood testing can miss celiac disease if you produce very little IgA. This is also relevant when interpreting research on stool IgA assays, but the antibody class measured by this test must be confirmed before applying that limitation to it.
• Diet and medication context: gluten restriction and immune-suppressing treatment can weaken blood antibody responses used in a celiac evaluation. Their effects on this particular stool index have not been established.

What a Trend Can Mean

Repeated measurements of this stool index haven't been validated against intestinal healing or changes in symptoms. A falling result cannot establish recovery, and a stable result cannot establish continuing disease. Even using the same laboratory doesn't resolve that uncertainty.

Blood antibodies have an established place in celiac follow-up, though they also have limits. A meta-analysis found that blood tTG-IgA detected fewer than half of the people whose biopsies still showed intestinal damage while they followed a gluten-free diet.